Loading…
Cancer Patient Protection Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
33pct
2d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Cancer Patient Protection Act of 2015 This bill requires any new presidential sequestration order for FY2016-FY2017 to declare that no reduction shall be made with respect to payments for physician-administered drugs and biologicals under part B (Supplementary Medical Insurance) of title XVIII (Medicare) of the Social Security Act to the extent that such payments are made based on their average sales price. The Government Accountability Office must examine the shift of cancer care from physician-run community cancer clinics to hospitals and its consequences to costs to the federal government and to Medicare beneficiaries for cancer care under the Medicare program.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on the Budget, and in addition to the Committees on Ways and Means, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · fourth_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Client expense: $340,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
HR 5122, legislation to prohibit further action on the Centers for Medicare & Medicaid Services (CMS) proposed rule for the Medicare Part B Drug Demo H.R. 5001/S.2822, the Flexibility in Electronic Health Record (EHR) Reporting Act HR 1416 The Cancer Patient Protection Act of 2015 Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Client expense: $65,519 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Client expense: $610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.
Client expense: $560,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2016 · third_quarter · Medicare/Medicaid
HR 5122, legislation to prohibit further action on the Centers for Medicare & Medicaid Services (CMS) proposed rule for the Medicare Part B Drug Demo H.R. 5001/S.2822, the Flexibility in Electronic Health Record (EHR) Reporting Act HR 1416 The Cancer Patient Protection Act of 2015 Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Client expense: $169,982 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
2016 · third_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.
Client expense: $810,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2016 · second_quarter · Medicare/Medicaid
- Medicare Patient Access to Cancer Treatment Act (H.R. 2895) - Prompt pay discount legislation, (HR 696 / S 506) - H.R. 1416 The Cancer Patient Protection Act of 2015 - site neutrality for ambulatory oncology services - Oppose proposed Medicare Part B drug payment demonstration (no specific bill)
Client expense: Not reported · Firm income: $40,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
- Medicare Patient Access to Cancer Treatment Act (H.R. 2895) - Prompt pay discount legislation, (HR 696 / S 506) - H.R. 1416 The Cancer Patient Protection Act of 2015 - site neutrality for ambulatory oncology services
Client expense: Not reported · Firm income: $40,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015 H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare Part B Prescription Drug Models
2016 · second_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
HR 5122, legislation to prohibit further action on the Centers for Medicare & Medicaid Services (CMS) proposed rule for the Medicare Part B Drug Demo H.R. 5001/S.2822, the Flexibility in Electronic Health Record (EHR) Reporting Act HR 1416 The Cancer Patient Protection Act of 2015 Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Client expense: $92,141 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.
Client expense: $780,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2016 · second_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) and possible Senate companion bill. Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, and Medicare reimbursement for cancer care. CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement.
Client expense: $186,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) and possible Senate companion bill. Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care. CMS/CMMI Medicare Part B Payment Model to cut Medicare Part B drug reimbursement.
Client expense: $92,700 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Monitor federal issues and legislation related to healthcare policy. Monitor implementation of the Patient Protection and Affordable Care Act (P.L. 111-148). Monitor federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER) (P.L. 109-60). Monitor federal and legislative activity related to Medicare Reimbursement. Monitor the implementation of Consolidated Appropriations Act, 2016 (P.L. 114-113). Extend Section 3111, P.L. 111-148. H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10). H.R. 6, House 21st Century Cures Act. H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act of 2015. H.R. 1416, Cancer Patient Protection Act of 2015. H.R. 1600, Patients' Access to Treatments Act of 2015. H.R. 1725, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015. H.R. 1859, Ensuring Children's Access to Specialty Care Act of 2015. S. 480, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015. H.R. 2256, Veterans Information Modernization Act. H.R. 2464, Demanding Accountability for Veterans Act of 2015. H.R. 3020, House Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. S. 1695, Senate Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. H.R. 4227, Medicare Advantage Bill of Rights. S. 2392, Medicare Advantage Bill of Rights.
Client expense: $110,000 · Firm income: Not reported
2016 · first_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015 Medicare Part B Drug Payment Model Proposed Rule
Client expense: $515,000 · Firm income: Not reported
2016 · first_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client expense: $290,000 · Firm income: Not reported
2016 · first_quarter · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
HR 1416 The Cancer Patient Protection Act of 2015 Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Client expense: $98,340 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project.
Client expense: $690,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2015 · second_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
Client expense: $670,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2015 · fourth_quarter · Medicare/Medicaid
- Medicare Patient Access to Cancer Treatment Act (H.R. 2895) - Prompt pay discount legislation, HR 696 - H.R. 1416 The Cancer Patient Protection Act of 2015 - site neutrality for ambulatory oncology services
Client expense: Not reported · Firm income: $40,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
HR 1416 The Cancer Patient Protection Act of 2015
Client expense: $53,150 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10); Monitor implementation, P.L. 114-10; Monitor implementation of the Patient Protection and Affordable Care Act, P.L. 111-148; Extend Section 3111, P.L. 111-148; H.R. 1416, Cancer Patient Protection Act of 2015; H.R. 775 / S. 539, Medicare Access to Rehabilitation Services Act of 2015; H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act of 2015; H.R. 3261 / S. 1884 Medicare Prescription Drug Savings and Choice Act of 2015; H.R. 4227 / S. 2392, Medicare Advantage Bill of Rights.
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act H.R. 1314, Bipartisan Budget Act of 2015
Client expense: $335,000 · Firm income: Not reported
2015 · fourth_quarter · Medicare/Medicaid
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client expense: $260,000 · Firm income: Not reported
2015 · fourth_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
Client expense: $85,800 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Client expense: $820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
Client expense: $780,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2015 · third_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
Client expense: $89,700 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
--Site-neutral payment policy for oncology services under Medicare, - Medicare Patient Access to Cancer Treatment Act (H.R. 2895) - Prompt pay discount legislation, HR 696 - H.R. 1416 The Cancer Patient Protection Act of 2015 - site neutrality for ambulatory oncology services
Client expense: Not reported · Firm income: $40,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10); Monitor implementation, P.L. 114-10; Monitor implementation, P.L. 111-148; Extend Section 3111, P.L. 111-148; H.R. 1416, Cancer Patient Protection Act of 2015; H.R. 775 / S. 539, Medicare Access to Rehabilitation Services Act of 2015; H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act of 2015; H.R. 3261 / S. 1884 Medicare Prescription Drug Savings and Choice Act of 2015
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
Part D Drug Coverage and Patient Access ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures Initiatives, H.R.6, 21st Century Cures Act S. 506, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client expense: $235,000 · Firm income: Not reported
2015 · third_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1416 Cancer Patient Protection Act of 2015 H.R. 2895, the Medicare Patient Access to Cancer Treatment Act
Client expense: $202,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
HR 1416 The Cancer Patient Protection Act of 2015
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148). Monitor federal issues and legislation associated with health care policy. H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10). H.R. 6, House 21st Century Cures Act. H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act of 2015. H.R. 775, Medicare Access to Rehabilitation Services Act of 2015. S. 539, Medicare Access to Rehabilitation Services Act of 2015. H.R. 1600, Patients' Access to Treatments Act of 2015. H.R. 1416, Cancer Patient Protection Act of 2015. H.R. 1859, Ensuring Children's Access to Specialty Care Act of 2015. H.R. 2126, Cutting Costly Codes Act of 2015. H.R. 2247, ICD-TEN Act. H.R. 3020, House Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. S. 1695, Senate Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. S.1376, National Defense Authorization Act for Fiscal Year 2016. H.R. 3309, Flex-IT 2 Act. H.R. 3261, Medicare Prescription Drug Savings and Choice Act of 2015. S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015.
Client expense: Not reported · Firm income: $60,000
2015 · third_quarter · Budget/Appropriations
Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148). Monitor federal issues and legislation associated with health care policy. H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10). H.R. 6, House 21st Century Cures Act. H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act of 2015. H.R. 775, Medicare Access to Rehabilitation Services Act of 2015. S. 539, Medicare Access to Rehabilitation Services Act of 2015. H.R. 1600, Patients' Access to Treatments Act of 2015. H.R. 1416, Cancer Patient Protection Act of 2015. H.R. 1859, Ensuring Children's Access to Specialty Care Act of 2015. H.R. 2126, Cutting Costly Codes Act of 2015. H.R. 2247, ICD-TEN Act. H.R. 3020, House Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. S. 1695, Senate Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015. S.1376, National Defense Authorization Act for Fiscal Year 2016. H.R. 3309, Flex-IT 2 Act. H.R. 3261, Medicare Prescription Drug Savings and Choice Act of 2015. S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015.
Client expense: Not reported · Firm income: $60,000
2015 · third_quarter · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
Client expense: $850,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2015 · second_quarter · Medicare/Medicaid
Legislation to reform Medicare payment for oncology: Cancer Care Payment Reform Act (H.R. 1934) Legislation to stop CMS from applying the sequester cut to Medicare Part B drugs (H.R. 1416). Legislation to exclude manufacturer-to-distributor prompt pay discounts from the calculation of ASP-based Medicare Part B drug reimbursement rates (H.R. 696, S. 506). Legislation to fix the sustainable growth rate (SGR) that is the basis for Medicare reimbursement of physician services (H.R. 2). Misc. discussions (no legislation) to address 340B drug discount program, site-of-service payment parity, Medicare 14-day rule, and Medicare reimbursement for cancer care.
Client expense: $98,800 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
HR 696 and S 506, prompt pay legislation; health IT and meaningful use; radiation and reimbursement issues; SGR Medicare physician payments; H.R.1416 Cancer Patient Protection Act of 2015; site neutral payments; 21st Century Cures
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medicare/Medicaid
HR 2 The Medicare Access and CHIP Reauthorization Act HR 1416 The Cancer Patient Protection Act of 2015
Client expense: $51,986 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medicare/Medicaid
H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10); Monitor implementation, P.L. 114-10; Monitor implementation, P.L. 111-148; Extend Section 3111, P.L. 111-148; H.R. 1416, Cancer Patient Protection Act of 2015; H.R. 775 / S. 539, Medicare Access to Rehabilitation Services Act of 2015; H.R. 270, Flexibility in Health IT Reporting (Flex-IT) Act of 2015
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medicare/Medicaid
Physician and pharmacy reimbursement issues and implementation of the Affordable Care Act. H.R. 696 To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 H.R. 1416 Cancer Patient Protection Act of 2015
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medicare/Medicaid
Part D Drug Coverage and Patient Access ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least Costly Alternative Policy Changes re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures Initiatives, H.R.6, 21st Century Cures Act S. 506, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client expense: $260,000 · Firm income: Not reported
| Democratic |
| NY |
| Vern Buchanan | Republican | FL |
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $280,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE